NCT03618550 2026-04-16
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
8 trialsNCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
NCT07001618 2026-04-03
IMMUNOLIFE2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT05999994 2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2 Recruiting
NCT07021989 2026-03-17
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
NCT07203729 2026-03-16
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06875128 2026-03-13
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Delcath Systems Inc.
Phase 2 Recruiting
NCT07420439 2026-02-19
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Not yet recruiting